Download PDF
Planta Med 2019; 85(17): 1316-1325
DOI: 10.1055/a-1019-9819
Biological and Pharmacological Activity
Reviews
Georg Thieme Verlag KG Stuttgart · New York

Natural Compounds with Anti-BACE1 Activity as Promising Therapeutic Drugs for Treating Alzheimerʼs Disease

Mehjabeen Naushad‡
1   Department of Microbiology, School of Life Sciences, Central University of Tamil Nadu, Tiruvarur, India
,
Siva Sundara Kumar Durairajan‡
1   Department of Microbiology, School of Life Sciences, Central University of Tamil Nadu, Tiruvarur, India
,
Amal Kanti Bera
2   Department of Biotechnology, Indian Institute of Technology Madras, Chennai, India
,
Sanjib Senapati
2   Department of Biotechnology, Indian Institute of Technology Madras, Chennai, India
,
Min Li
3   Neuroscience Research Laboratory, Mr. & Mrs. Ko Chi-Ming Centre for Parkinsonʼs Disease Research, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong SAR, China
› Author Affiliations
Further Information

Publication History

received 08 April 2019
revised 24 September 2019

accepted 26 September 2019

Publication Date:
16 October 2019 (online)

Also available at
   Permissions and Reprints

Abstract

Alzheimerʼs disease is a neurodegenerative disease that leads to irreversible neuronal damage. Senile plaques, composed of amyloid beta peptide, is the principal abnormal characteristic of the disease. Among the factors involved, the secretase enzymes, namely, α secretase, beta-site amyloid precursor protein-cleaving enzyme, β secretase, and γ secretase, hold consequential importance. Beta-site amyloid precursor protein-cleaving enzyme 1 is considered to be the rate-limiting factor in the production of amyloid beta peptide. Research supporting the concept of inhibition of beta-site amyloid precursor protein-cleaving enzyme activity as one of the effective therapeutic targets in the mitigation of Alzheimerʼs disease is well accepted. The identification of natural compounds, such as β-amyloid precursor protein-selective beta-site amyloid precursor protein-cleaving enzyme inhibitors, and the idea of compartmentalisation of the beta-site amyloid precursor protein-cleaving enzyme 1 action have caused a dire need to closely examine the natural compounds and their effectiveness in the disease mitigation. Many natural compounds have been reported to effectively modulate beta-site amyloid precursor protein-cleaving enzyme 1. At lower doses, compounds like 2,2′,4′-trihydroxychalcone acid, quercetin, and myricetin have been shown to effectively reduce beta-site amyloid precursor protein-cleaving enzyme 1 activity. The currently used five drugs that are marketed and used for the management of Alzheimerʼs disease have an increased risk of toxicity and restricted therapeutic efficiency, hence, the search for new anti-Alzheimerʼs disease drugs is of primary concern. A variety of natural compounds having pure pharmacological moieties showing multitargeting activity and others exhibiting specific beta-site amyloid precursor protein-cleaving enzyme 1 inhibition as discussed below have superior biosafety. Many of these compounds, which are isolated from medicinal herbs and marine flora, have been long used for the treatment of various ailments since ancient times in the Chinese and Ayurvedic medical systems. The aim of this article is to review the available data on the selected natural compounds, giving emphasis to the inhibition of beta-site amyloid precursor protein-cleaving enzyme 1 activity as a mode of Alzheimerʼs disease treatment.

Key words

Alzheimerʼs disease - BACE1 - BACE1 inhibitors - flavonoids - phenolics - alkaloids - terpenes
 

  • References

  • 1 Golde TE, DeKosky ST, Galasko D. Alzheimerʼs disease: The right drug, the right time. Science 2018; 362: 1250-1251
    CrossrefPubMedGoogle Scholar
  • 2 World Health Organization. Dementia. Available at: https://www.who.int/news-room/fact-sheets/detail/dementia Accessed September 21, 2019
    PubMedGoogle Scholar
  • 3 Scheltens P, Blennow K, Breteler MM, de Strooper B, Frisoni GB, Salloway S, Van der Flier WM. Alzheimerʼs disease. Lancet 2016; 388: 505-517
    CrossrefPubMedGoogle Scholar
  • 4 Koss DJ, Jones G, Cranston A, Gardner H, Kanaan NM, Platt B. Soluble pre-fibrillar tau and β-amyloid species emerge in early human Alzheimerʼs disease and track disease progression and cognitive decline. Acta Neuropathol 2016; 1326: 875-895
    PubMedGoogle Scholar
  • 5 Selkoe DJ. Physiological production of the beta-amyloid protein and the mechanism of Alzheimerʼs disease. Trends Neurosci 1993; 16: 403-409
    CrossrefPubMedGoogle Scholar
  • 6 Edbauer D, Winkler E, Regula JT, Pesold B, Steiner H, Haass C. Reconstitution of gamma-secretase activity. Nat Cell Biol 2003; 5: 486-488
    CrossrefPubMedGoogle Scholar
  • 7 Dislich B, Lichtenthaler SF. The membrane-bound aspartyl protease BACE1: molecular and functional properties in Alzheimerʼs disease and beyond. Front Physiol 2012; 17: 3-8
    PubMedGoogle Scholar
  • 8 Hussain I, Powell D, Howlett DR, Tew DG, Meek TD, Chapman C, Gloger IS, Murphy KE, Southan CD, Ryan DM, Smith TS, Simmons DL, Walsh FS, Dingwall C, Christie G. Identification of a novel aspartic protease (Asp 2) as beta-secretase. Mol Cell Neurosci 1999; 14: 419-427
    CrossrefPubMedGoogle Scholar
  • 9 Lin X, Koelsch G, Wu S, Downs D, Dashti A, Tang J. Human aspartic protease memapsin 2 cleaves the beta-secretase site of beta-amyloid precursor protein. Proc Natl Acad Sci U S A 2000; 97: 1456-1460
    CrossrefPubMedGoogle Scholar
  • 10 Fukumoto H, Rosene DL, Moss MB, Raju S, Hyman BT, Irizarry MC. Beta-secretase activity increases with aging in human, monkey, and mouse brain. Am J Pathol 2004; 164: 719-725
    CrossrefPubMedGoogle Scholar
  • 11 Bennett BD, Babu-Khan S, Loeloff R, Louis JC, Curran E, Citron M, Vassar R. Expression analysis of BACE2 in brain and peripheral tissues. J Biol Chem 2000; 275: 20647-20651
    CrossrefPubMedGoogle Scholar
  • 12 Farzan M, Schnitzler CE, Vasilieva N, Leung D, Choe H. BACE2, a beta-secretase homolog, cleaves at the beta-site and within the amyloid-beta region of the amyloid-beta precursor protein. Proc Natl Acad Sci U S A 2000; 97: 9712-9717
    CrossrefPubMedGoogle Scholar
  • 13 Voytyuk I, Mueller SA, Herber J, Snellinx A, Moechars D, van Loo G, Lichtenthaler SF, De Strooper B. BACE2 distribution in major brain cell types and identification of novel substrates. Life Sci Alliance 2018; 1: e201800026
    CrossrefPubMedGoogle Scholar
  • 14 Roberds SL, Anderson J, Basi G, Bienkowski MJ, Branstetter DG, Chen KS, Freedman SB, Frigon NL, Games D, Hu K, Johnson-Wood K, Kappenman KE, Kawabe TT, Kola I, Kuehn R, Lee M, Liu W, Motter R, Nichols NF, Power M, Robertson DW, Schenk D, Schoor M, Shopp GM, Shuck ME, Sinha S, Svensson KA, Tatsuno G, Tintrup H, Wijsman J, Wright S, McConlogue L. BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimerʼs disease therapeutics. Hum Mol Genet 2001; 12: 1317-1324
    PubMedGoogle Scholar
  • 15 Luo Y, Bolon B, Kahn S, Bennett BD, Babu-Khan S, Denis P, Fan W, Kha H, Zhang J, Gong Y, Martin L, Louis JC, Yan Q, Richards WG, Citron M, Vassar R. Mice deficient in BACE1, the Alzheimerʼs β-secretase, have normal phenotype and abolished β-amyloid generation. Nat Neurosci 2001; 4: 231-232
    PubMedGoogle Scholar
  • 16 Jonsson T, Atwal JK, Steinberg S, Snaedal J, Jonsson PV, Bjornsson S, Stefansson H, Sulem P, Gudbjartsson D, Maloney J, Hoyte K, Gustafson A, Liu Y, Lu Y, Bhangale T, Graham RR, Huttenlocher J, Bjornsdottir G, Andreassen OA, Jönsson EG, Palotie A, Behrens TW, Magnusson OT, Kong A, Thorsteinsdottir U, Watts RJ, Stefansson K. A mutation in APP protects against Alzheimerʼs disease and age-related cognitive decline. Nature 2012; 488: 96-99
    PubMedGoogle Scholar
  • 17 Fan LY, Chiu MJ. Combotherapy and current concepts as well as future strategies for the treatment of Alzheimerʼs disease. Neuropsychiatr Dis Treat 2014; 10: 439-451
    PubMedGoogle Scholar
  • 18 Anand R, Gill KD, Mahdi A. Therapeutics of Alzheimerʼs disease: past, present and future. Neuropharmacol 2013; 76: 27-50
    PubMedGoogle Scholar
  • 19 Cummings J, Lee G, Ritter A, Zhong K. Alzheimerʼs disease drug development pipeline. Alzheimers Dement (N Y) 2018; 4: 195-214
    PubMedGoogle Scholar
  • 20 Piton M, Hirtz C, Desmetz C, Milhau J, Lajoix AD, Bennys K, Lehmann S, Gabelle A. Alzheimerʼs disease: advances in drug development. J Alzheimers Dis 2018; 65: 3-13
    CrossrefPubMedGoogle Scholar
  • 21 Mullard A. BACE inhibitor bust in Alzheimer trial. Nat Rev Drug Discov 2017; 16: 155
    PubMedGoogle Scholar
  • 22 Buggia-Prévot V, Fernandez CG, Riordan S, Vetrivel KS, Roseman J, Waters J, Bindokas VP, Vassar R, Thinakaran G. Axonal BACE1 dynamics and targeting in hippocampal neurons: a role for Rab11 GTPase. Mol Neurodegener 2014; 9: 1
    CrossrefPubMedGoogle Scholar
  • 23 Gautam V, DʼAvanzo C, Hebisch M, Kovacs DM, Kim DY. BACE1 activity regulates cell surface contactin-2 levels. Mol Neurodegener 2014; 9: 4
    CrossrefPubMedGoogle Scholar
  • 24 Yan R. Physiological functions of the β-site amyloid precursor protein cleaving enzyme 1 and 2. Front Mol Neurosci 2017; 10: 97
    PubMedGoogle Scholar
  • 25 Ben Halima S, Mishra S, Raja KMP, Willem M, Baici A, Simons K, Brüstle O, Koch P, Haass C, Caflisch A, Rajendran L. Specific inhibition of β-secretase processing of the Alzheimer disease amyloid precursor protein. Cell Rep 2016; 14: 2127-2141
    CrossrefPubMedGoogle Scholar
  • 26 Descamps O, Spilman P, Zhang Q, Libeu CP, Poksay K, Gorostiza O, Campagna J, Jagodzinska B, Bredesen DE, John V. AβPP-selective BACE inhibitors (ASBI): novel class of therapeutic agents for Alzheimerʼs disease. J Alzheimers Dis 2013; 37: 343-355
    CrossrefPubMedGoogle Scholar
  • 27 Gao D, Sakurai K, Chen J, Ogiso T. Protection by baicalein against ascorbic acid-induced lipid peroxidation of rat liver microsomes. Res Commun Mol Pathol Pharmacol 1995; 90: 103-114
    PubMedGoogle Scholar
  • 28 Zhang SQ, Obregon D, Ehrhart J, Deng J, Tian J, Hou H, Giunta B, Sawmiller D, Tan J. Baicalein reduces β-amyloid and promotes non amyloidogenic amyloid precursor protein processing in an Alzheimerʼs disease transgenic mouse model. J Neurosci Res 2013; 91: 1239-1246
    CrossrefPubMedGoogle Scholar
  • 29 Xue X, Liu H, Qi L, Li X, Guo C, Gong D, Qu H. Baicalein ameliorated the upregulation of striatal glutamatergic transmission in the mice model of Parkinsonʼs disease. Brain Res Bull 2014; 103: 54-59
    CrossrefPubMedGoogle Scholar
  • 30 Paris D, Mathura V, Ait-Ghezala G, Beaulieu-Abdelahad D, Patel N, Bachmeier C, Mullan M. Flavonoids lower Alzheimerʼs Aβ production via an NFκB dependent mechanism. Bioinformation 2011; 6: 229-236
    CrossrefPubMedGoogle Scholar
  • 31 Lu JH, Ardah MT, Durairajan SSK, Liu LF, Xie LX, Fong WF, Hasan MY, Huang JD, El-Agnaf OM, Li M. Baicalein inhibits formation of α-synuclein oligomers within living cells and prevents Aβ peptide fibrillation and oligomerisation. Chembiochem 2011; 12: 615-624
    CrossrefPubMedGoogle Scholar
  • 32 Gu XH, Xu LJ, Liu ZQ, Wei B, Yang YJ, Xu GG, Yin XP, Wang W. The flavonoid baicalein rescues synaptic plasticity and memory deficits in a mouse model of Alzheimerʼs disease. Behav Brain Res 2016; 311: 309-321
    CrossrefPubMedGoogle Scholar
  • 33 Durairajan SSK, Huang YY, Yuen PY, Chen LL, Kwok KY, Liu LF, Song JX, Han QB, Xue L, Chung SK, Huang JD, Baum L, Senapati S, Li M. Effects of Huanglian-jie-du-tang and its modified formula on the modulation of amyloid-β precursor protein processing in Alzheimerʼs disease models. PLoS One 2014; 9: e92954
    CrossrefPubMedGoogle Scholar
  • 34 Yang S, Liu W, Lu S, Tian YZ, Wang WY, Ling TJ, Liu RT. A novel multifunctional compound camellikaempferoside b decreases Aβ production, interferes with Aβ aggregation, and prohibits Aβ-mediated neurotoxicity and neuroinflammation. ACS Chem Neurosci 2016; 7: 505-518
    CrossrefPubMedGoogle Scholar
  • 35 Priprem A, Watanatorn J, Sutthiparinyanont S, Phachonpai W, Muchimapura S. Anxiety and cognitive effects of quercetin liposomes in rats. Nanomedicine 2008; 4: 70-78
    CrossrefPubMedGoogle Scholar
  • 36 Shimmyo Y, Kihara T, Akaike A, Niidome T, Sugimoto H. Flavonols and flavones as BACE1 inhibitors: structure-activity relationship in cell-free, cell-based and in silico studies reveal novel pharmacophore features. Biochim Biophys Acta 2008; 1780: 819-825
    CrossrefPubMedGoogle Scholar
  • 37 Lu J, Wu DM, Zheng YL, Hu B, Zhang ZF, Shan Q, Zheng ZH, Liu CM, Wang YJ. Quercetin activates AMP-activated protein kinase by reducing PP2C expression protecting old mouse brain against high cholesterol-induced neurotoxicity. Pathol 2010; 222: 199-212
    CrossrefPubMedGoogle Scholar
  • 38 Semwal DK, Semwal RB, Combrinck S, Viljoen A. Myricetin: A dietary molecule with diverse biological activities. Nutrients 2016; 8: 90
    CrossrefPubMedGoogle Scholar
  • 39 Umadevi I, Daniel M, Sabnis SD. Chemotaxonomic studies on some members of Anacardiaceae. Proc Plant Sci 1988; 98: 205-208
    PubMedGoogle Scholar
  • 40 Shimmyo Y, Kihara T, Akaike A, Niidome T, Sugimoto H. Multifunction of myricetin on A beta: neuroprotection via a conformational change of A beta and reduction of A beta via the interference of secretases. J Neurosci Res 2007; 24: 368-377
    PubMedGoogle Scholar
  • 41 Ramezani M, Darbandi N, Khodagholi F, Hashemi A. Myricetin protects hippocampal CA3 pyramidal neurons and improves learning and memory impairments in rats with Alzheimerʼs disease. Neural Regen Res 2016; 11: 1976-1980
    CrossrefPubMedGoogle Scholar
  • 42 Ono K, Yoshiike Y, Takashima A, Hasegawa K, Naiki H, Yamada M. Potent anti-amyloidogenic and fibril-destabilizing effects of polyphenols in vitro: implications for the prevention and therapeutics of Alzheimerʼs disease. J Neurochem 2003; 87: 172-181
    PubMedGoogle Scholar
  • 43 Vallés SL, Borrás C, Gambini J, Furriol J, Ortega A, Sastre J, Pallardó FV, Viña J. Oestradiol or genistein rescues neurons from amyloid beta-induced cell death by inhibiting activation of p38. Aging Cell 2008; 7: 112-118
    CrossrefPubMedGoogle Scholar
  • 44 Valles SL, Dolz-Gaiton P, Gambini J, Borras C, Lloret A, Pallardo FV, Viña J. Estradiol or genistein prevent Alzheimerʼs disease-associated inflammation correlating with an increase PPAR gamma expression in cultured astrocytes. Brain Res 2010; 1312: 138-144
    CrossrefPubMedGoogle Scholar
  • 45 Ma W, Ding B, Yu H, Yuan L, Xi Y, Xiao R. Genistein alleviates b-amyloid induced inflammatory damage through regulating toll-like receptor 4/nuclear factor κB. J Med Food 2015; 18: 273-279
    CrossrefPubMedGoogle Scholar
  • 46 Tsai TH. Concurrent measurement of unbound genistein in the blood, brain and bile of anesthetized rats using microdialysis and its pharmacokinetic application. J Chromatogr A 2005; 1073: 317-322
    CrossrefPubMedGoogle Scholar
  • 47 Chen W, Chen G. Danshen (Salvia miltiorrhiza Bunge): A prospective healing sage for cardiovascular diseases. Curr Pharm Des 2017; 23: 5125-5135
    PubMedGoogle Scholar
  • 48 Gao Y, Zhang K, Zhu F, Wu Z, Chu X, Zhang X, Zhang Y, Zhang J, Chu L. Salvia miltiorrhiza (Danshen) inhibits L-type calcium current and attenuates calcium transient and contractility in rat ventricular myocytes. J Ethnopharmacol 2014; 158: 397-403
    CrossrefPubMedGoogle Scholar
  • 49 Zhou X, Chan SW, Tseng HL, Deng Y, Hoi PM, Choi PS, Or PM, Yang JM, Lam FF, Lee SM, Leung GP, Kong SK, Ho HP, Kwan YW, Yeung JH. Danshensu is the major marker for the antioxidant and vasorelaxation effects of Danshen (Salvia miltiorrhiza) water-extracts produced by different heat water-extractions. Phytomedicine 2012; 19: 1263-1269
    CrossrefPubMedGoogle Scholar
  • 50 Jiang RW, Lau KM, Hon PM, Mak TC, Woo KS, Fung KP. Chemistry and biological activities of caffeic acid derivatives from Salvia miltiorrhiza . Curr Med Chem 2005; 12: 237-246
    CrossrefPubMedGoogle Scholar
  • 51 Lin YH, Liu AH, Wu HL, Westenbroek C, Song QL, Yu HM, Ter Horst GJ, Li XJ. Salvianolic acid B, an antioxidant from Salvia miltiorrhiza, prevents Abeta(25–35)-induced reduction in BPRP in PC12 cells. Biochem Biophys Res Commun 2006; 348: 593-599
    CrossrefPubMedGoogle Scholar
  • 52 Durairajan SSK, Yuan Q, Xie L, Chan WS, Kum WF, Koo I, Liu C, Song Y, Huang JD, Klein WL. Salvianolic acid B inhibits Ab fibril formation and disaggregates preformed fibrils and protects against Ab-induced cytotoxicity. Neurochem Int 2008; 52: 741-750
    CrossrefPubMedGoogle Scholar
  • 53 Tang Y, Huang D, Zhang MH, Zhang WS, Tang YX, Shi ZX, Deng L, Zhou DH, Lu XY. Salvianolic Acid B inhibits Aβ generation by modulating BACE1 activity in SH-SY5Y-APPsw cells. Nutrients 2016; 8: 333
    CrossrefPubMedGoogle Scholar
  • 54 Durairajan SSK, Chirasani VR, Shetty SG, Iyaswamy A, Malampati S, Song J, Liu L, Huang J, Senapati S, Li M. Decrease in the generation of amyloid-β due to salvianolic acid B by modulating BACE1 activity. Curr Alzheimer Res 2017; 14: 1-9
    CrossrefPubMedGoogle Scholar
  • 55 Yu T, Paudel P, Seong SH, Kim JA, Jung HA, Choi JS. Computational insights into β-site amyloid precursor protein enzyme 1 (BACE1) inhibition by tanshinones and salvianolic acids from Salvia miltiorrhiza via molecular docking simulations. Comput Biol Chem 2018; 74: 273-285
    CrossrefPubMedGoogle Scholar
  • 56 Mori T, Koyama N, Guillot-Sestier MV, Tan J, Town T. Ferulic acid is a nutraceutical β-secretase modulator that improves behavioural impairment and Alzheimer-like pathology in transgenic mice. PLoS One 2013; 8: e55774
    CrossrefPubMedGoogle Scholar
  • 57 Srinivasan M, Sudheer AR, Menon VP. Ferulic acid: therapeutic potential through its antioxidant property. J Clin Biochem Nutr 2007; 40: 92-100
    CrossrefPubMedGoogle Scholar
  • 58 Kawabata K, Yamamoto T, Hara A, Shimizu M, Yamada Y, Matsunaga K, Tanaka T, Mori H. Modifying effects of ferulic acid on azoxymethane-induced colon carcinogenesis in F344 rats. Cancer Lett 2000; 157: 15-21
    CrossrefPubMedGoogle Scholar
  • 59 Sultana R, Ravagna A, Mohmmad-Abdul H, Calabrese V, Butterfield DA. Ferulic acid ethyl ester protects neurons against amyloid β-peptide (1–42)-induced oxidative stress and neurotoxicity: relationship to antioxidant activity. J Neurochem 2005; 92: 749-758
    CrossrefPubMedGoogle Scholar
  • 60 Qin J, Chen D, Lu W, Xu H, Yan C, Hu H, Chen B, Qiao M, Zhao X. Preparation, characterization, and evaluation of liposomal ferulic acid in vitro and in vivo . Drug Dev Ind Pharm 2008; 34: 602-608
    CrossrefPubMedGoogle Scholar
  • 61 Mori T, Rezai-Zadeh K, Koyama N, Arendash GW, Yamaguchi H, Kakuda N, Horikoshi-Sakuraba Y, Tan J, Town T. Tannic acid is a natural β-secretase inhibitor that prevents cognitive impairment and mitigates Alzheimer-like pathology in transgenic mice. J Biol Chem 2012; 287: 6912-6927
    CrossrefPubMedGoogle Scholar
  • 62 Durairajan SSK, Liu LF, Lu JH, Chen LL, Yuan Q, Chung SK, Huang L, Li XS, Huang JD, Li M. Berberine ameliorates β-amyloid pathology, gliosis, and cognitive impairment in an Alzheimerʼs disease transgenic mouse model. Neurobiol Aging 2012; 33: 2903-2919
    CrossrefPubMedGoogle Scholar
  • 63 Asai M, Iwata N, Yoshikawa A, Aizaki Y, Ishiura S, Saido TC. Maruyama K: Berberine alters the processing of Alzheimerʼs amyloid precursor protein to decrease Abeta secretion. Biochem Biophys Res Commun 2007; 352: 498-502
    CrossrefPubMedGoogle Scholar
  • 64 Tan XS, Ma JY, Feng R, Ma C, Chen WJ, Sun YP, Fu J, Huang M, He CY, Shou JW, He WY, Wang Y, Jiang JD. Tissue distribution of berberine and its metabolites after oral administration in rats. PLoS One 2013; 8: e77969
    CrossrefPubMedGoogle Scholar
  • 65 Panahi N, Mahmoudian M, Mortazavi P, Hashjin GS. Effects of berberine on beta-secretase activity in a rabbit model of Alzheimerʼs disease. Arch Med Sci 2013; 9: 146-150
    PubMedGoogle Scholar
  • 66 Cai Z, Wang C, He W, Chen Y. Berberine alleviates amyloid-beta pathology in the brain of app/ps1 transgenic mice via inhibiting β/γ-secretases activity and enhancing α-secretases. Curr Alzheimer Res 2018; 15: 1045-1052
    CrossrefPubMedGoogle Scholar
  • 67 Jung HA, Min BS, Yokozawa T, Lee JH, Kim YS, Choi JS. Anti-Alzheimer and antioxidant activities of Coptidis rhizoma alkaloids. Biol Pharm Bull 2009; 32: 1433-1438
    CrossrefPubMedGoogle Scholar
  • 68 Chu M, Chen X, Wang J, Guo L, Wang Q, Gao Z, Kang J, Zhang M, Feng J, Guo Q, Li B, Zhang C, Guo X, Chu Z, Wang Y. Polypharmacology of berberine based on multi-target binding motifs. Front Pharmacol 2018; 9: 801
    CrossrefPubMedGoogle Scholar
  • 69 Zhang H, Zhao C, Cao G, Guo L, Zhang S, Liang Y, Qin C, Su P, Li H, Zhang W. Berberine modulates amyloid-β peptide generation by activating AMP-activated protein kinase. Neuropharmacol 2017; 125: 408-417
    CrossrefPubMedGoogle Scholar
  • 70 Zhu Z, Li C, Wang X, Yang Z, Chen J, Hu L, Jiang H, Shen X. 2,2′,4′-trihydroxychalcone from Glycyrrhiza glabra as a new specific BACE1 inhibitor efficiently ameliorates memory impairment in mice. J Neurochem 2010; 114: 374-385
    CrossrefPubMedGoogle Scholar
  • 71 Youn K, Jun M. Biological evaluation and docking analysis of potent BACE1 inhibitors from Boesenbergia rotunda . Nutrients 2019; 11: 662
    CrossrefPubMedGoogle Scholar
  • 72 James S, Aparna JS, Paul AM, Lankadasari MB, Mohammed S, Binu VS, Santhoshkumar TR, Reshmi G, Harikumar KB. Cardamonin inhibits colonic neoplasia through modulation of microRNA expression. Sci Rep 2017; 7: 13945
    CrossrefPubMedGoogle Scholar
  • 73 Leirós M, Alonso E, Rateb ME, Houssen WE, Ebel R, Jaspars M, Alfonso A, Botana L. Gracilins: Spongionella-derived promising compounds for Alzheimer disease. Neuropharmacol 2015; 93: 285-293
    CrossrefPubMedGoogle Scholar
  • 74 Leirós M, Sánchez JA, Alonso E, Rateb ME, Houssen WE, Ebel R, Jaspars M, Alfonso A, Botana LM. Spongionella secondary metabolites protect mitochondrial function in cortical neurons against oxidative stress. Mar Drugs 2014; 12: 700-718
    CrossrefPubMedGoogle Scholar
  • 75 Chen F, Eckman EA, Eckman CB. Reductions in levels of the Alzheimerʼs amyloid beta peptide after oral administration of ginsenosides. FASEB J 2006; 20: 1269-1271
    CrossrefPubMedGoogle Scholar
  • 76 Ji ZN, Dong TT, Ye WC, Choi RC, Lo CK, Tsim KW. Ginsenoside Re attenuate beta-amyloid and serum-free induced neurotoxicity in PC12 cells. J Ethnopharmacol 2006; 107: 48-52
    CrossrefPubMedGoogle Scholar
  • 77 Cao G, Su P, Zhang S, Guo L, Zhang H, Liang Y, Qin C, Zhang W. Ginsenoside Re reduces Aβ production by activating PPARγ to inhibit BACE1 in N2a/APP695 cells. Eur J Pharmacol 2016; 793: 101-108
    CrossrefPubMedGoogle Scholar
  • 78 Wang YH, Du GH. Ginsenoside Rg1 inhibits beta-secretase activity in vitro and protects against Abeta-induced cytotoxicity in PC12 cells. J Asian Nat Prod Res 2009; 11: 604-612
    CrossrefPubMedGoogle Scholar
  • 79 Qi C, Bao J, Wang J, Zhu H, Xue Y, Wang X, Li H, Sun W, Gao W, Lai Y, Chen JG, Zhang Y. Asperterpenes A and B, two unprecedented meroterpenoids from Aspergillus terreus with BACE1 inhibitory activities. Chem Sci 2016; 7: 6563-6572
    CrossrefPubMedGoogle Scholar
  • 80 Qi C, Liu M, Zhou Q, Gao W, Chen C, Lai Y, Hu Z, Xue Y, Zhang J, Li D, Li XN, Zhang Q, Wang J, Zhu H, Zhang Y. BACE1 inhibitory meroterpenoids from Aspergillus terreus . J Nat Prod 2018; 81: 1937-1945
    CrossrefPubMedGoogle Scholar
  • 81 Qi C, Qiao Y, Gao W, Liu M, Zhou Q, Chen C, Lai Y, Xue Y, Zhang J, Li D, Wang J, Zhu H, Hu Z, Zhou Y, Zhang Y. New 3,5-dimethylorsellinic acid-based meroterpenoids with BACE1 and AchE inhibitory activities from Aspergillus terreus . Org Biomol Chem 2018; 16: 9046-9052
    CrossrefPubMedGoogle Scholar
  • 82 Voytyuk I, De Strooper B, Chavez-Gutierrez L. Modulation of γ- and β-secretases as early prevention against Alzheimerʼs disease. Biol Psychiatry 2018; 83: 320-327
    CrossrefPubMedGoogle Scholar